Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Other Working Capital Changes (2010 - 2026)

Perspective Therapeutics' (CATX) quarterly Other Working Capital Changes came in at $155000.0 in Q2 2026, down 52.6% quarter-over-quarter from $327000.0 in Q1 2026.

Analysis

Perspective Therapeutics (CATX) Other Working Capital Changes (2010 - 2026) Analysis & Trends

Perspective Therapeutics has disclosed Other Working Capital Changes across 17 years of filings, most recently posting $155000.0 for Q2 2026.

  • In Q2 2026, Other Working Capital Changes changed N/A year-over-year to $155000.0; the TTM figure through Jun 2026 stood at $482000.0 (up 134.43% YoY), while the FY2025 annual figure was -$1.4 million, down 105.0% from the prior year.
  • Other Working Capital Changes came in at $155000.0 for Q2 2026 at Perspective Therapeutics, down from $327000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $28.0 million in Q1 2024 to a low of -$1.4 million in Q1 2025.
  • Average Other Working Capital Changes over 5 years is $2.3 million, with a median of $191000.0 recorded in 2022.
  • Year-over-year, Other Working Capital Changes tumbled 9900.0% in 2022 and soared 46566.67% in 2024.
  • Over 5 years, Other Working Capital Changes stood at $249000.0 in 2022, then surged by 35.34% to $337000.0 in 2023, then soared by 8208.61% to $28.0 million in 2024, then slumped by 105.0% to -$1.4 million in 2025, then jumped by 111.07% to $155000.0 in 2026.
  • Per Business Quant data, the three most recent Other Working Capital Changes figures were $155000.0 in Q2 2026, $327000.0 in Q1 2026, and -$1.4 million in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Perspective Therapeutics 361.95 Mn 361.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 155,000.00
Jun 30, 2026 155,000.00
Mar 31, 2026 327,000.00
Mar 31, 2026 327,000.00
Mar 31, 2025 -1.40 Mn
Mar 31, 2025 -1.40 Mn
Mar 31, 2024 28.00 Mn
Mar 31, 2024 28.00 Mn
Dec 31, 2023 337,000.00
Dec 31, 2023 337,000.00
Sep 30, 2023 -457,000.00
Sep 30, 2023 -457,000.00
Jun 30, 2023 385,000.00
Jun 30, 2023 385,000.00
Mar 31, 2023 60,000.00
Mar 31, 2023 60,000.00
Dec 31, 2022 249,000.00
Dec 31, 2022 249,000.00
Sep 30, 2022 227,000.00
Sep 30, 2022 227,000.00